Northern Trust Corp cut its stake in shares of BioTime, Inc. (NYSEAMERICAN:BTX) by 63.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 326,020 shares of the biotechnology company’s stock after selling 562,850 shares during the quarter. Northern Trust Corp owned about 0.29% of BioTime worth $1,027,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of BTX. GSA Capital Partners LLP acquired a new stake in BioTime in the 2nd quarter valued at about $246,000. Nationwide Fund Advisors lifted its holdings in BioTime by 61.2% in the 2nd quarter. Nationwide Fund Advisors now owns 71,857 shares of the biotechnology company’s stock valued at $226,000 after purchasing an additional 27,279 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in BioTime in the 2nd quarter valued at about $142,000. Teachers Advisors LLC lifted its holdings in BioTime by 8.7% in the 2nd quarter. Teachers Advisors LLC now owns 130,670 shares of the biotechnology company’s stock valued at $412,000 after purchasing an additional 10,501 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in BioTime by 52.7% in the 2nd quarter. Alliancebernstein L.P. now owns 83,700 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 28,900 shares in the last quarter.
In related news, Director Broadwood Partners, L.P. acquired 2,692,307 shares of the business’s stock in a transaction dated Friday, October 13th. The shares were acquired at an average cost of $2.60 per share, for a total transaction of $6,999,998.20. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of BioTime, Inc. (NYSEAMERICAN BTX) traded down $0.05 during mid-day trading on Thursday, hitting $2.46. 271,200 shares of the stock traded hands, compared to its average volume of 352,725. BioTime, Inc. has a 1-year low of $2.19 and a 1-year high of $3.97.
A number of research analysts have issued reports on BTX shares. Zacks Investment Research lowered shares of BioTime from a “hold” rating to a “sell” rating in a report on Friday, October 20th. BidaskClub lowered shares of BioTime from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 18th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $5.08.
TRADEMARK VIOLATION NOTICE: “BioTime, Inc. (BTX) Stake Decreased by Northern Trust Corp” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/12/07/biotime-inc-btx-stake-decreased-by-northern-trust-corp.html.
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.